Has Fernando Caceres, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,181 in general payments to Fernando Caceres, MD across 20 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fernando Caceres, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fernando Caceres, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fernando Caceres, MD

Pulmonary Disease · Billings, MTNPI 1225281033

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,627 of the $2,181 with a category attached, or 74.6%. Olympus Corporation Of The Americas accounts for 78.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,639 and has fallen 98.6% since, to $24 in 2024.

$2,181in general payments, 2019–2025

Across 20 payments — averaging $109.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Olympus Corporation Of The Americas$2K
Abiomed$174
Johnson & Johnson$130
Genentech USA, Inc.$80
GSK$66
Boehringer Ingelheim$15

What the payments were for

Travel & lodging$1,62775%
Food & beverage$45921%
Education$954%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Olympus Corporation Of The Americas	12	$1,716
Abiomed	2	$174
Johnson & Johnson	1	$130
Genentech USA, Inc.	2	$80
GSK	2	$66
Boehringer Ingelheim	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,181 in reported general payments places this provider in the 75th percentile of 43 pulmonary disease providers in Montana.

See all pulmonary disease providers in Montana →

Medicare billing

Part B allowed, 2024

$74,562

Medicare patients

246

Services billed

601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Spiriva RespimatTiotropium Bromide	41	$48,212
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	44	$42,465
Spiriva HandihalerTiotropium Bromide	18	$23,887
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	58	$15,884
SymbicortBudesonide/Formoterol Fumarate	29	$12,288
Advair HfaFluticasone Propion/Salmeterol	13	$9,448
Incruse ElliptaUmeclidinium Bromide	17	$8,664
Qvar RedihalerBeclomethasone Dipropionate	24	$8,319
Breo ElliptaFluticasone/Vilanterol	12	$7,056
BreynaBudesonide/Formoterol Fumarate	19	$4,986
Roflumilast	38	$4,497
Albuterol Sulfate HfaAlbuterol Sulfate	78	$3,062
Ventolin HfaAlbuterol Sulfate	23	$1,822
Mycophenolate Mofetil	13	$1,805
Azithromycin	41	$1,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta	$66	$58,18573 claims
Boehringer IngelheimSpiriva Respimat	$15	$48,21241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 pulmonary disease providers in Montana.

Other pulmonary disease in Billings

Vineeth KumarBillings$2K
Frederick KahnBillings$1K
Manfred BaumgartnerBillings$1K
Aleksandra KwasnikBillings$840
Andrew FischerBillings$755
Nicole PhilipsBillings$520
David PucciBillings$441
Erin RainsBillings$161
Randol HooperBillings$70
Robert MerchantBillings$26

See the full list for Montana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →